Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.45 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6251202 | 1.00 | CA2 (0.63) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL3861238 | 1.00 | CA2 (0.63) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL7204823 | 1.00 | CA2 (0.63) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL3855790 | 1.00 | CA2 (0.63) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL7212250 | 1.00 | CA2 (0.63) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL1672036 | 1.00 | CA2 (0.63) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL276768 | 1.00 | CA2 (0.63) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL3452084 | 1.00 | CA2 (0.63) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL7209672 | 1.00 | CA2 (0.63) | CA2CA1GRIK1GRIK2SLC1A2 | |
| Hydrochloric Acid SCHEMBL25419337 | 0.98 | CA2 (0.61) | CA2CA1GRIK1GRIK2SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218010-A1 | Methods of Producing Sulfated Oligosaccharide Derivatives and Intermediates Thereof | PROGEN PG500 SERIES PTY LTD (AU) | 2024-07-04 | — | — | US | claimed |
| EP-4301764-A1 | METHODS OF PRODUCING SULFATED OLIGOSACCHARIDE DERIVATIVES AND INTERMEDIATES THEREOF | Progen PG500 Series Pty Ltd (AU) | 2024-01-10 | — | — | EP | claimed |
| CN-114525120-A | Non-flowback clean acidification blockage removal working solution and preparation method and application thereof | 宁夏朔光石油科技有限公司 | 2022-05-24 | — | — | CN | claimed |
| US-RE46955-E1 | Sulfated oligosaccharide derivatives | PROGEN PG500 SERIES PTY LTD (AU) | 2018-07-17 | — | — | US | claimed |
| EP-2205616-B1 | NOVEL SULFATED OLIGOSACCHARIDE DERIVATIVES | PROGEN PHARMACEUTICALS LTD (AU) | 2016-04-27 | — | — | EP | claimed |
| US-20150065440-A1 | SULFATED OLIGOSACCHARIDE DERIVATIVES | PROGEN PG500 SERIES PTY LTD (AU) | 2015-03-05 | — | — | US | claimed |
| US-8828952-B2 | Sulfated oligosaccharide derivatives | PROGEN PHARMACEUTICALS LIMITED (AU) | 2014-09-09 | — | — | US | claimed |
| US-20110245196-A1 | NOVEL SULFATED OLIGOSACCHARIDE DERIVATIVES | PROGEN PG500 SERIES PTY LTD (AU) | 2011-10-06 | — | — | US | claimed |
| EP-2205616-A1 | NOVEL SULFATED OLIGOSACCHARIDE DERIVATIVES | Progen Pharmaceuticals Limited (AU) | 2010-07-14 | — | — | EP | claimed |
| WO-2009049370-A1 | NOVEL SULFATED OLIGOSACCHARIDE DERIVATIVES | PROGEN PHARMACEUTICALS LIMITED (AU) | 2009-04-23 | — | — | WO | claimed |
| US-6605638-B1 | Treating multidrug resistant tumors; increasing drug bioavailability | D-PHARM LIMITED (IL) | 2003-08-12 | — | — | US | claimed |
| US-20240218010-A1 | Methods of Producing Sulfated Oligosaccharide Derivatives and Intermediates Thereof | PROGEN PG500 SERIES PTY LTD (AU) | 2024-07-04 | — | — | US | disclosed |
| EP-4301764-A1 | METHODS OF PRODUCING SULFATED OLIGOSACCHARIDE DERIVATIVES AND INTERMEDIATES THEREOF | Progen PG500 Series Pty Ltd (AU) | 2024-01-10 | — | — | EP | disclosed |
| CN-117279612-A | Cosmetic product | 株式会社资生堂 | 2023-12-22 | — | — | CN | disclosed |
| WO-2022183254-A1 | METHODS OF PRODUCING SULFATED OLIGOSACCHARIDE DERIVATIVES AND INTERMEDIATES THEREOF | PROGEN PG500 SERIES PTY LTD (AU) | 2022-09-09 | — | — | WO | disclosed |
| WO-2003000173-A2 | USE OF BRANCHED-CHAIN FATTY ACIDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN | D-PHARM LIMITED (IL) | 2003-01-03 | — | — | WO | disclosed |
| US-20020042445-A1 | Use of branched-chain fatty acids and derivatives thereof for the treatment of pain | D-PHARM LTD. (IL) | 2002-04-11 | — | — | US | disclosed |
| US-6251946-B1 | SATURATED OR UNSATURATED BRANCHED FATTY ACID CONTAINING LIPID ESTER OR FATTY ACID AMIDE TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS, INCLUDING EPILEPSY, MIGRAINES, CHRONIC PAIN AND BIPOLAR DISORDERS | D-PHARM LTD. (IL) | 2001-06-26 | — | — | US | disclosed |
| EP-1009734-A1 | BRANCHED CHAIN FATTY ACIDS, THEIR DERIVATIVES AND USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | D-PHARM, LTD. (IL) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999002485-A1 | BRANCHED CHAIN FATTY ACIDS, THEIR DERIVATIVES AND USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | D-PHARM LTD. (IL) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218010-A1 | Methods of Producing Sulfated Oligosaccharide Derivatives and Intermediates Thereof | OSTC, FUT5, NPY5R | CA2 1637/4885CA1 1645/4885GRIK1 1539/4885 |
| US-20020042445-A1 | Use of branched-chain fatty acids and derivatives thereof for the treatment of pain | OPRL1, ELOVL5, ELOVL1 | CA2 1189/4885CA1 2400/4885GRIK1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.